Home » Stocks » SNY

Sanofi S.A. (SNY)

Stock Price: $46.59 USD 0.69 (1.50%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 117.23B
Revenue (ttm) 45.57B
Net Income (ttm) 15.02B
Shares Out 1.25B
EPS (ttm) 1.94
PE Ratio 24.02
Forward PE 12.25
Dividend $3.53
Dividend Yield 7.58%
Trading Day March 5
Last Price $46.59
Previous Close $45.90
Change ($) 0.69
Change (%) 1.50%
Day's Open 46.20
Day's Range 46.01 - 46.65
Day's Volume 3,172,319
52-Week Range 37.62 - 55.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 day ago

The FDA accepts Sanofi's (SNY) sBLA for review of Dupixent for treating moderate-to-severe asthma in children aged six-11 years. A verdict from the FDA is expected on Oct 21, 2021.

The Motley Fool - 2 days ago

It's a real possibility.

Other stocks mentioned: GSK
Benzinga - 3 days ago

The FDA has accepted for review the supplemental marketing application seeking approval for Dupixent (dupilumab). It is an add-on treatment for children aged 6 to 11 years with uncontrolled mo...

GlobeNewsWire - 3 days ago

Sanofi's Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members

PRNewsWire - 1 week ago

STOCKHOLM, Feb. 26, 2021 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that it is entering into a joint Phase II clinical study to treat patients with multiple myeloma using XNK'...

Benzinga - 1 week ago

Health Canada has approved Sanofi's SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) DUPIXENT (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis i...

Other stocks mentioned: REGN
Business Wire - 1 week ago

MUNICH--(BUSINESS WIRE)-- #AAV--SIRION Biotech announced that it signed a license and collaboration agreement with Sanofi.

Benzinga - 1 week ago

The FDA approved expanded use of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi's SA (NASDAQ: SNY) immunotherapy Libtayo (cemiplimab-rwlc) as monotherapy in newly diagnosed advanced l...

Other stocks mentioned: REGN
GlobeNewsWire - 1 week ago

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règ...

Proactive Investors - 1 week ago

Sanofi and GlaxoSmithKline PLC (LON:GSK) have announced details of a phase II study for their collaborative coronavirus vaccine. Britain's Glaxo and France's Sanofi are the world's two largest...

Other stocks mentioned: GSK
New York Post - 1 week ago

The drugmakers pushed back the rollout of their experimental COVID-19 shot in December because a study found it generated an "insufficient" immune response to the virus in people older than 50...

Other stocks mentioned: GSK
Benzinga - 1 week ago

Sanofi SA (NASDAQ: SNY)and GlaxoSmithKline Plc (NYSE: GSK) have initiated a new Phase 2 study with 720 volunteers aged 18 and finalize the antigen dosage for Phase 3 evaluation of their adjuva...

Other stocks mentioned: GSK
GlobeNewsWire - 1 week ago

Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Other stocks mentioned: GSK
Benzinga - 2 weeks ago

Bristol-Myers Squibb Co (NYSE: BMY) and Sanofi SA (NASDAQ: SNY) were ordered to pay the state of Hawaii more than $834 million for illegally marketing their blood-thinning drug Plavix, Bloombe...

Other stocks mentioned: BMY
Reuters - 2 weeks ago

A judge in Hawaii on Monday ordered Bristol-Myers Squibb Co and Sanofi SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from its bl...

Other stocks mentioned: BMY
Reuters - 3 weeks ago

A COVID-19 vaccine candidate developed by Sanofi and U.S. group Translate Bio "will not be ready this year," the French drugmaker's chief executive told Le Journal du Dimanche newspaper.

Benzinga - 3 weeks ago

Sanofi SA (NASDAQ: SNY) has launched a takeover offer for Kiadis Pharma NV (OTC: KIADF) to represent an aggregate adjusted equity value of €308 million. The takeover offer is priced at €5.45 p...

GlobeNewsWire - 3 weeks ago

This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 4 paragraph 1, A...

Zacks Investment Research - 3 weeks ago

The FDA approves Sanofi (SNY)/Regeneron's Libtayo for treating patients with advanced/metastatic basal cell carcinoma. The is the second approved indication for the drug in the United States.

Other stocks mentioned: REGN
Benzinga - 3 weeks ago

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) immunotherapy Libtayo (cemiplimab-rwlc) has scored approval from the FDA for the treatment of advanced basal cell car...

Other stocks mentioned: REGN
CNBC Television - 1 month ago

Sanofi CEO says Dupixent eczema drug is game-changing for company

"This is a once in a generation medicine," Sanofi CEO Paul Hudson said of Dupixent, a therapy for allergic diseases such as eczema, asthma and nasal polyps that's seeing rapid sales growth.

Zacks Investment Research - 1 month ago

Sanofi's (SNY) Q4 earnings and sales miss estimates. Dupixent drives sales growth in the quarter

Benzinga - 1 month ago

Shares of Sanofi (NASDAQ:SNY) rose 2.7% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 3.33% over the past year to $1.45, which may not ...

Benzinga - 1 month ago

Sanofi SA (NASDAQ: SNY) posted a profit for the fourth quarter of 2020 at €1.08 billion, a turnaround from a loss of €10 million a year ago. However, sales came at €9.38 billion, down 2.4% yea...

GlobeNewsWire - 1 month ago

Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology

GlobeNewsWire - 1 month ago

Q4 2020 sales growth(2) of 4.2% and business EPS growth of 9.8% at CER

Zacks Investment Research - 1 month ago

Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Seeking Alpha - 1 month ago

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating).

Other stocks mentioned: BIIB, BTI, GSK, IMBBY, LMT, MO, MRK, RHHBY
Zacks Investment Research - 1 month ago

Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.

Other stocks mentioned: GILD, JNJ, LLY, MRK, VRTX
Zacks Investment Research - 1 month ago

Sanofi (SNY) to support manufacturing and supply of BioNTech's COVID-19 vaccine candidate, which the latter has developed in partnership with Pfizer.

Other stocks mentioned: BNTX
CNBC International TV - 1 month ago

Sanofi to help produce doses of Pfizer-BioNTech Covid vaccine

CNBC's Charlotte Reed reports on Sanofi lending a hand to produce 125 million doses of the Pfizer-BioNTech Covid-19 vaccine after it suffered a setback in the development of its own vaccine.

Other stocks mentioned: BNTX, PFE
Market Watch - 1 month ago

Unusual collaboration will see Sanofi supply more than 125 million doses of Pfizer–BioNTech COVID shot from the summer.

Other stocks mentioned: BNTX, PFE
Benzinga - 1 month ago

Other stocks mentioned: BNTX, PFE
GlobeNewsWire - 1 month ago

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règ...

GlobeNewsWire - 1 month ago

Sanofi, Capgemini, Generali and Orange announce the creation of a digital ecosystem dedicated to e-health, a first in Europe

Other stocks mentioned: CGEMY, ORAN
Seeking Alpha - 1 month ago

Sanofi is a big pharma company trading at a low valuation and paying a 3.5% dividend. Dupixent and flu vaccine sales growth boosted revenue in the latest quarter and the deep drug pipeline is ...

Seeking Alpha - 1 month ago

Part 2 of the series will search the European market for value. Sanofi is a big pharma company trading at a low valuation and paying a 3.5% dividend.

Other stocks mentioned: TOT, UL, VGK
Seeking Alpha - 1 month ago

Sanofi (SNY) CEO Paul Hudson Presents at 39th Annual JPMorgan Virtual Healthcare Conference - (Transcript)

The Motley Fool - 1 month ago

After divesting its active pharmaceutical ingredient segment, the slimmed-down company will have more time to focus on developing new blockbuster drugs.

GlobeNewsWire - 1 month ago

SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer

The Motley Fool - 1 month ago

Their coronavirus projects fell behind, faltered, or failed.

Other stocks mentioned: CSLLY, MRK
GuruFocus - 1 month ago

The Invesco European Growth Fund (Trades, Portfolio) disclosed last week that its top five trades during the fiscal fourth quarter included new holdings in Heineken NV (XAMS:HEIA), TGS-NOPEC G...

Other stocks mentioned: HEINY
InvestorPlace - 1 month ago

Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.

Other stocks mentioned: ABBV, BMY, JNJ, NVS, PFE, TAK
Zacks Investment Research - 1 month ago

Sanofi's (SNY) potential acquisition of Kymab, a private biotech, is set to strengthen its presence in immunology.

Reuters - 1 month ago

French drugmaker Sanofi has agreed to buy British immunotherapy firm Kymab for up to $1.45 billion, the latest in a string of deals as it belatedly expands in a fast-growing medical area.

GlobeNewsWire - 1 month ago

Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L

Seeking Alpha - 2 months ago

Wide-Moat Stocks On Sale - The January 2021 Heat Map

Other stocks mentioned: BIIB, BK, BTI, GSK, IMBBY, INTC, LMT, MO, MRK, RHHBY
InvestorPlace - 2 months ago

These 6 cannabis stocks show promise in the medical and recreational ends of the burgeoning marijuana sector, set to grow even more in 2021. The post 6 Cannabis Stocks to Buy as the U.S. Softe...

Other stocks mentioned: CARA, CGC, GRWG, MRK, TRSSF
GlobeNewsWire - 2 months ago

   

The Motley Fool - 2 months ago

Hopefully, the backup plan works.

Other stocks mentioned: GSK

About SNY

Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for... [Read more...]

Industry
Drug Manufacturers-General
CEO
Paul Hudson
Employees
99,412
Stock Exchange
NASDAQ
Ticker Symbol
SNY
Full Company Profile

Financial Performance

In 2020, Sanofi's revenue was 37.37 billion, a decrease of -0.70% compared to the previous year's 37.63 billion. Earnings were 12.31 billion, an increase of 338.85%.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Sanofi stock is "Buy." The 12-month stock price forecast is 64.67, which is an increase of 38.81% from the latest price.

Price Target
$64.67
(38.81% upside)
Analyst Consensus: Buy